Cellectis S.A. (CLLS)
NASDAQ: CLLS · Real-Time Price · USD
1.030
-0.050 (-4.63%)
Nov 2, 2026, 2:53 PM EST - Market open
Cellectis Revenue
Cellectis had revenue of $6.90M in the quarter ending June 30, 2026, a decrease of -62.05%. This brings the company's total for the last twelve months to $63.82M, up 0.61% year-over-year. In the year 2025, Cellectis had annual revenue of $79.59M with 61.72% growth.
Revenue (ttm)
$63.82M
Revenue Growth
+0.61%
P/S Ratio
1.32
Revenue / Employee
$278,703
Employees
229
Market Cap
80.36M
Revenue by Geography
- France 72.95M 91.7%
- Unallocated 6.64M 8.3%
Fiscal year ended Dec 31, 2025 See the full Cellectis breakdown
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | 79.59M | 30.38M | 61.72% |
| Dec 31, 2024 | 49.22M | 40.02M | 435.37% |
| Dec 31, 2023 | 9.19M | -16.53M | -64.26% |
| Dec 31, 2022 | 25.72M | -12.87M | -33.35% |
| Dec 31, 2021 | 38.60M | -20.97M | -35.20% |
| Dec 31, 2020 | 59.56M | 36.57M | 159.09% |
| Dec 31, 2019 | 22.99M | 1.56M | 7.27% |
| Dec 31, 2018 | 21.43M | -12.28M | -36.43% |
| Dec 31, 2017 | 33.72M | -22.73M | -40.27% |
| Dec 31, 2016 | 56.45M | -4.78M | -7.81% |
| Dec 31, 2015 | 61.22M | 29.22M | 91.29% |
| Dec 31, 2014 | 32.01M | 14.51M | 82.92% |
| Dec 31, 2013 | 17.50M | -10.25M | -36.93% |
| Dec 31, 2012 | 27.74M | 7.04M | 34.00% |
| Dec 31, 2011 | 20.70M | -248.54K | -1.19% |
| Dec 31, 2010 | 20.95M | 6.11M | 41.19% |
| Dec 31, 2009 | 14.84M | -2.65M | -15.16% |
| Dec 31, 2008 | 17.49M | - | - |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. It does not take any expenses into account and is therefore different from profits.
Related Stocks
| Company Name | Revenue |
|---|---|
| Tonix Pharmaceuticals Holding | 29.10M |
| Coya Therapeutics | 8.02M |
| Atara Biotherapeutics | 6.19M |
| NeurAxis | 5.32M |
| Rani Therapeutics Holdings | 4.88M |
| Rallybio | 434.00K |
| NeOnc Technologies Holdings | 39.99K |
CLLS News
- 5 days ago - Cellectis S.A. Presents Preclinical Data Highlighting Efficient APOC3 Editing and Marked Triglyceride Reduction with .HEAL-101 at ESGCT 2026 - Nasdaq
- 5 days ago - Cellectis' .HEAL-101 Lowers Triglycerides In Preclinical Study; Phase 1 Data Expected In H2'27 - Nasdaq
- 6 days ago - Cellectis Presents Preclinical Data Highlighting Efficient APOC3 Editing and Marked Triglyceride Reduction with .HEAL-101 at ESGCT 2026 - GlobeNewsWire
- 11 days ago - INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Cellectis S.A. - CLLS - PRNewsWire
- 13 days ago - INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Cellectis S.A. – CLLS - GlobeNewsWire
- 18 days ago - Securities Fraud Investigation Into Cellectis S.A. (CLLS) Continues – Shareholders Who Lost Money Urged To Contact Glancy Prongay Wolke & Rotter LLP, a Leading Securities Fraud Law Firm - GlobeNewsWire
- 18 days ago - Cellectis S.A. (CLLS) Shareholders Who Lost Money – Contact Law Offices of Howard G. - GlobeNewsWire
- 18 days ago - Securities Fraud Investigation Into Cellectis S.A. (CLLS) Continues – Shareholders Who Lost Money Urged To Contact The Law Offices of Frank R. - GlobeNewsWire